Anaphore to Present Company Overview with Focus on Atrimer Technology Platform at 13th Annual C21 BioVentures Conference

LA JOLLA, Calif., May 17, 2011 /PRNewswire/ -- Anaphore Inc. today announced that Katherine Bowdish, Ph.D., chief executive officer of Anaphore, will present a company overview at the 13th Annual C21 BioVentures conference. The presentation is scheduled for 4 p.m. PDT on Wednesday, May 25, at The Meritage Resort in Napa, Calif.  

About Anaphore

Anaphore is developing a new class of protein pharmaceuticals to address significant unmet medical needs for patients with serious diseases. The company's Atrimer technology platform originates in tetranectin, a human plasma protein of trivalent structure. Each of the three binding domains comprises five distinct amino-acid loops that can be programmed to bind potently and specifically to virtually any target of interest.  Atrimer therapeutics potentially offer biological, manufacturing, and commercial advantages over currently marketed therapies. Atrimer protein therapeutics are protected by intellectual property, including multiple patent families.

Anaphore's initial therapeutic focus is immunology and oncology. In collaboration with select partners, Anaphore is committed to realizing the full promise of Atrimer therapeutics against targets in a wide range of therapeutic areas, including rare diseases.

Anaphore recently formed a partnership with Mitsubishi Tanabe Pharma Corporation to discover and develop Atrimer drug candidates for the treatment of autoimmune disorders. Since its founding in 2008, Anaphore has raised $38 million in financing from top-tier biotechnology investors 5AM Ventures, Versant Ventures, Apposite Capital LLP, SR One, Merck Serono Ventures and Aravis SA.

For more information please visit www.anaphore.com.

Media Contact:

Ian Stone or David Schull
Russo Partners, LLC
619-528-2220
[email protected]
[email protected]

SOURCE Anaphore Inc.